How many patents does
The Wistar Institute have?
patents
347
families
93
granted
61
applications
286
US
143
WO
70
EP
33
CN
11
JP
4
KR
3
RoW
83
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
The Wistar Institute
Top ten assignees appearing on patents
2009 - 2018
| wyeth | 7 |
| inovio pharmaceuticals | 5 |
| valley health system | 4 |
| crusade laboratories | 3 |
| vical | 2 |
| novelos therapeutics | 1 |
| bayer healthcare | 1 |
| bayer | 1 |
| virttu biologics | 1 |
2009
| wyeth | 7 |
The Wistar Institute
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| methods of inducing a cytotoxic immune response and recombinant simian adenovirus compos… 🛈 | 19 | 2001 |
| ebna1 inhibitors and their method of use | 14 | 2013 |
| method for identifying a compound that modulates telomerase activity | 14 | 2007 |
| method for diagnosing lung cancers using gene expression profiles in peripheral blood mo… 🛈 | 13 | 2007 |
| ebna1 inhibitors and methods using same | 12 | 2015 |
| compositions and methods for targeting stromal cells for the treatment of cancer | 11 | 2012 |
| methods and compositions for diagnosing or detecting lung cancers | 10 | 2015 |
| compositions and methods for delivery of genetic material | 10 | 1993 |
| methods and compositions for treatment of metastatic and refractory cancers and tumors | 8 | 2015 |
| compositions and methods for modulating the activity of epstein-barr nuclear antigen 1 | 7 | 2011 |